Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
13F holders, Q1 2022
Institutional positions in Repligen Corp as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 450
- −53 vs. Q4 2021
- Shares held
- 48.7M
- +1.48M (+3.1%) vs. Q4 2021
- Total value
- $9.15B
- −$3.34B (−26.7%) vs. Q4 2021
- New holders
- 42
- 180 more added
- Sold out
- 95
- 143 more reduced
5 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RGEN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 481 | $9.00B |
| Q1 2026 | 445 | $7.75B |
| Q4 2025 | 475 | $10.2B |
| Q3 2025 | 453 | $8.00B |
| Q2 2025 | 446 | $7.22B |
| Q1 2025 | 441 | $7.33B |
| Q4 2024 | 431 | $8.09B |
| Q3 2024 | 445 | $8.25B |
| Q2 2024 | 455 | $7.06B |
| Q1 2024 | 487 | $10.3B |
| Q4 2023 | 467 | $10.4B |
| Q3 2023 | 440 | $9.08B |
| Q2 2023 | 448 | $7.74B |
| Q1 2023 | 448 | $9.06B |
| Q4 2022 | 443 | $9.06B |
| Q3 2022 | 434 | $9.56B |
| Q2 2022 | 406 | $8.17B |
| Q1 2022 | 450 | $9.15B |
| Q4 2021 | 508 | $12.5B |
| Q3 2021 | 481 | $13.6B |
| Q2 2021 | 430 | $9.28B |
| Q1 2021 | 459 | $8.88B |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Repligen Corp; share changes are against Q4 2021.